Introduction
Although germ cell tumors (GCTs) account for only 1% of male malignancies in the United States, it is the most common malignancy in men aged 20-35 years. [1] [2] [3] On the basis of histological findings, GCT can be divided in two subgroups: seminoma and nonseminoma. Mixed GCTs account for 30-50% of GCT. 4 Choriocarcinoma is seen usually as a small component of mixed GCT in 4-17% of GCT. [5] [6] [7] As a pure lesion it is very rare, with a frequency of less than 1% of all GCTs. 3, 5 Choriocarcinoma is defined as a GCT composed of two mixed distinct cell population, cytotrophoblast and syncytiotrophoblast, which contain high level of human chorionic gonadotropin (hCG). 4 hCG levels above 50 000 mIU/ml are predictive of a poor prognosis. [8] [9] [10] Pure choriocarcinoma of the testis is the most aggressive form of GCT tumor, with a high propensity to hematogenous spread at the time of initial diagnosis. Logothetis 11 previously described a choriocarcinoma syndrome. Our definition of choriocarcinoma syndrome refers to a clinical presentation of patients with normal testes by palpation and ultrasound, normal serum alpha-fetoprotein, and advanced hematogenous metastases with high level of hCG.
Metastatic GCTs are curable in 70-80% of cases.
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Pure choriocarcinoma of the testis or choriocarcinoma syndrome will present usually with serum hCG 450 000 mIU/ml and often with pulmonary and nonpulmonary visceral metastases. This accounts for the relatively poor prognosis. 8 Standard treatment for this tumor follows the guidelines for poor-risk nonseminomatous GCTs. 12 Patients with serum hCG 450 000 mIU/ml commonly have a plateau in the descent of their hCG with the third and fourth course of initial chemotherapy, and thus it may take several months after completion of chemotherapy before a serologic complete remission (CR) is achieved in patients who were cured with their initial chemotherapy. 10 It is difficult to ascertain the cure rate with initial chemotherapy for pure choriocarcinoma of testis or choriocarcinoma syndrome, but it is expected to be less than 50%. After progression, it is unknown whether these patients are curable with salvage chemotherapy. We report a retrospective review of 13 consecutive pure choriocarcinoma or choriocarcinoma syndrome patients treated with salvage high-dose chemotherapy (HDCT).
Patients and methods
Between April 1996 and October 2004, 184 germ cell patients were treated with salvage HDCT at Indiana University Hospital. 13 Thirteen of these patients had a diagnosis of pure choriocarcinoma of the testis or choriocarcinoma syndrome. As defined above, patients received salvage treatment as second-or third-line chemotherapy. Before HDCT, all patients had progressed following standard cisplatin combination therapy. Peripheral blood stem cells (PBSCs) were collected before HDCT as reported previously.
14 The patients were treated with a HDCT regimen of carboplatin 700 mg/m 2 and etoposide 750 mg/m 2 intravenously given for 3 consecutive days. The PBSC re-infusion was given on day 0. The second course of HDCT was given after hematopoietic recovery, usually 3-4 weeks after the first course. In patients achieving a CR, or normalization of tumor markers, maintenance daily etoposide was given in a dosage of 50 mg/m 2 orally for 21 consecutive days every 4 weeks for three cycles. 15 
Results
We evaluated 13 patients. Patients' characteristics are depicted in Table 1 . The median age was 38 years (range 17-56). Five patients had testis pure choriocarcinoma and eight patients choriocarcinoma syndrome. According to International Germ Cell Cancer Collaborative Group (IGCCCG), 12 patients had poor prognosis at diagnosis and only one intermediate. Seven patients were platinum refractory (serologic progression within 4 weeks of prior cisplatin combination therapy when they started HDCT). Ten patients received HDCT as second line and three patients as third line. All patients received two courses of HDCT, and six received maintenance daily oral etoposide. The median survival for the entire 13 patients was 19 months (range 5-90). Six patients (46%) remain alive and continuously disease free (cNED) at þ 19, þ 24, þ 38, þ 39, þ 57 and þ 75, (median follow-up, 37 months). Five patients achieved cNED status with chemotherapy alone and one patient achieved a CR with HDCT followed by surgical excision of teratoma. One additional patient (no. 8; Table 1 ) achieved a CR with HDCT, but relapsed 27 months later and was treated with third-line chemotherapy followed by two surgical resections of choriocarcinoma. He is currently alive NED at þ 90 months from initiation of HDCT.
Toxicity
Toxicity with HDCT has been reported previously. 14 No toxic deaths occurred in these patients. One patient developed acute myelogenous leukemia, at 1 year after HDCT. He had been treated with HDCT as third-line chemotherapy and did not receive daily oral etoposide. This patient was treated with allogenic bone marrow transplant, and is alive and disease-free of both leukemia and choriocarcinoma. 16 
Discussion
Pure coriocarcinoma is a rare cancer and represents less than 1% of GCTs. 4, 5, 7 In a medical review of 10 000 GCT, Ramon et al. 17 found 54 cases with an incidence of 0.05%. On gross examination, pure choriocarcinoma of the testis is a small tumor and often the testes appear normal. 5, 7 Choriocarcinomas are the most aggressive and rapidly growing GCTs with an high propensity for bleeding and hematogenous metastases. Usually sites of metastases are lungs, liver, brain, but also unusual sites like cutaneous. 18 Choriocarcinoma, as a component of a mixed tumor in the histology of the primary tumor, does not predict an adverse outcome. 19 However, patients with advanced pure choriocarcinoma or choriocarcinoma syndrome have a worse prognosis than other advanced/poor prognosis nonseminomatous GCTs, because of the very high levels of hCG and propensity for pulmonary and nonpulmonary visceral metastases. Batata 20 reported a series of pure choriocarcinoma with no long-term survival. Jensen and Venner 21 presented data from a population of 77 advanced germ cell patients treated with cisplatin-based therapy, of which three were pure choriocarcinoma. All the three patients with pure choriocarcinoma died. Patients who progress after first-line chemotherapy are treated with second-line therapy for GCT. Several regimens can be used, including standard dose regimens with cisplatin þ ifosfamide þ either vinblastine 22 or paclitaxel 23 or HDCT with PBSC transplantation. 13 Recurrent pure choriocarcinoma has a very poor prognosis. A large series from Indiana University of 135 GCTs failing first-line, platinum-based therapy, treated with salvage standard chemotherapy with vinblastine þ ifosfamide þ cisplatin, identified seven with choriocarcinoma syndrome. Thirty-two patients were longterm cNED, but all the seven choriocarcinoma syndrome patients died. 23 We reported a series of 184 GCTs treated with salvage HDCT at Indiana University Hospital. One hundred and sixteen of these patients (63%) are alive and cNED. 13 We present data of 13 patients from this population with pure choriocarcinoma or choriocarcinoma syndrome. Six patients (46%) are alive and cNED with a median follow-up of 37 months (range: 19-75). One additional patient, currently alive NED at þ 90 months from HDCT, relapsed and was cured by third-line paclitaxel-gemcitabine chemotherapy followed by two lung surgeries. Of the three patients treated in third-line setting, only one is alive compared to 6 of 10 treated as initial salvage therapy. Despite the small sample size, we feel this data provides evidence that patients with pure choriocarcinoma of the testis or choriocarcinoma syndrome can achieve long-term, disease-free survival and probably cure with HDCT salvage chemotherapy.
